4th Quarter - Report

MEHLMAN CONSULTING, INC. for MAYO CLINIC

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General healthcare; health reform; healthcare value and quality; health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability. Promoting biomedical research. Clinical laboratory capacity and reimbursement issues. Financial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19. Issues related to COVID vaccine distribution.

Contacted: HOUSE OF REPRESENTATIVES; Office of the Vice President of the United States; Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP)

Medicare/Medicaid MMM

General healthcare; health reform; healthcare value and quality; health information technology; clinical trials; tele-health; healthcare costs; healthcare interoperability. Promoting biomedical research. Rural health. Clinical laboratory capacity and reimbursement issues. Financial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19. H.R. 133 - Consolidated Appropriations Act, 2021.

Contacted: Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Office of the Vice President of the United States

Bills named: H.R. 133 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.